Recurrent Biliary Pain After Cholecystectomy: Sphincter of Oddi Dysfunction Without Rushing to Sphincterotomy
Recurrent biliary-type pain more than a year after cholecystectomy, with one real objective finding that places her outside the population a landmark negative trial actually studied.
Donna R., 55, had her gallbladder out fourteen months ago for symptomatic cholelithiasis and felt, for the first several months afterward, genuinely better — the postprandial pain that had sent her to a surgeon in the first place was gone. Over the past three months it's come back: recurrent episodic right-upper-quadrant and epigastric pain, not identical to before but close enough that she recognized it immediately. Blood drawn during two separate episodes showed a transient transaminase elevation — 2.4 and 2.2 times the upper limit of normal — returning to baseline between attacks; imaging has shown no dilation of the common bile duct on any occasion. The size of that elevation is what does the work here, not its bare presence: the Geenen-Hogan criteria ask for enzymes above twice the upper limit of normal on at least two separate occasions, and she clears that bar on both, which puts her in Type II sphincter of Oddi dysfunction rather than the pain-alone Type III classification — a distinction that turns out to matter more than it might sound like it should.
EPISOD, the trial that reshaped how the field thinks about treating post-cholecystectomy biliary pain, found that sphincterotomy performed no better than a sham procedure — but it studied Type III patients specifically, those with pain and no objective finding at all. Donna doesn't fit that population; she has the elevated enzyme EPISOD's negative result was never designed to speak to. What that leaves is a real, still-live question about how directly to proceed toward ERCP and possible sphincterotomy for a Type II presentation like hers, and a further, genuinely separate one about whether sphincter of Oddi manometry — itself carrying real complication risk and meaningful reader variability — needs to confirm the diagnosis first, or whether her objective finding already does enough of that work on its own. Donna has already tried acetaminophen and a brief course of an over-the-counter antacid on her own, neither of which touched the pain. What decides which literature speaks to her is not that an enzyme moved but how far it moved: had those episodes come back at 1.8 times normal rather than 2.4, she would sit in the marginal band Freeman and colleagues described, which behaves like Type III on manometry — and EPISOD's negative result would then be about her directly.
In clinic, weighing ERCP against a medical trial first
The field has moved meaningfully toward caution here since Cotton's EPISOD trial showed sphincterotomy performed no better than a sham procedure for patients whose only finding was biliary-type pain. Before pursuing ERCP — which in suspected sphincter of Oddi dysfunction carries a post-ERCP pancreatitis rate well above the background rate for ordinary ERCP — a trial of pharmacologic smooth-muscle relaxation is the lower-risk first step. Worth naming honestly, though: the randomized evidence for that step is Khuroo's crossover trial of nifedipine, not diltiazem, so we are borrowing across a drug class rather than citing the drug we intend to prescribe.
EPISOD's negative result was specifically about Type III patients — pain alone, no objective abnormality. She isn't that patient. Her transaminase elevation, documented above twice the upper limit of normal on two separate episodes rather than once and marginally, is exactly the kind of objective finding that keeps her in the Type II category EPISOD didn't declare futile, and that's the population where manometry-guided sphincterotomy has real, if imperfect, supporting evidence.
Treating "the field has moved toward caution" as though it applies uniformly to her case borrows a conclusion from a trial that excluded her from its own negative finding.
Before either of those plans moves forward, there's a real question sitting inside "proceed to ERCP" that hasn't been asked yet: does she need sphincter of Oddi manometry to confirm elevated basal pressure before sphincterotomy, or is empiric sphincterotomy reasonable in a well-selected Type II patient without it? Manometry itself carries real complication risk and meaningful interobserver variability in how it's read, and a genuine subset of the literature argues that in a patient who already has an objective abnormality, empiric treatment may be reasonable. That's not a reason to skip the medical trial being proposed; it's a separate fork worth deciding in advance, so that if the medical trial doesn't work, the team isn't debating manometry for the first time in the moment.
Agreed to a six-week trial of low-dose diltiazem with a structured pain diary, ERCP referral placed but held pending that outcome.
Not agreed: whether, if the medical trial fails, the next step should be manometry-guided or empiric sphincterotomy — the advanced endoscopist leans toward manometry given the diagnostic clarity it offers even with its own limitations, the pharmacologist thinks a well-documented Type II presentation may not need it. Left as a decision for that later conversation, not today's.